Literature DB >> 7571559

Staphylococcus aureus septic arthritis in patients on hemodialysis treatment.

S Slaughter1, R J Dworkin, D N Gilbert, J E Leggett, S Jones, R Bryant, M A Martin.   

Abstract

We retrospectively reviewed hospital discharge diagnoses of septic arthritis over an 11-year period (1982 through 1992) at 3 medical centers; 11 episodes of septic arthritis were identified in patients on hemodialysis treatment. Of the 11 episodes, 9 were caused by Staphylococcus aureus; in 8 of 9, the blood cultures were positive for the organism and the infection was monoarticular. Concurrent infection of the dialysis access site occurred in 4 cases. Two patients died (22%). We postulate that repeated skin trauma and contact with health care personnel and facilities result in a high rate of nasal carriage of S aureus and, hence, an increased risk of bacteremia with its attendant complications such as septic arthritis. The use of mupirocin nasal ointment is reported to eradicate or suppress carriage in a high percentage of patients; some studies report that long-term suppressive therapy reduces the frequency of S aureus bacteremia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7571559      PMCID: PMC1303006     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  34 in total

1.  Acute infectious arthritis in the aged and chronically ill.

Authors:  R F WILLKENS; L A HEALEY; J L DECKER
Journal:  Arch Intern Med       Date:  1960-09

Review 2.  Bacterial infections in chronic hemodialysis patients: epidemiologic and pathophysiologic aspects.

Authors:  M Goldman; J L Vanherweghem
Journal:  Adv Nephrol Necker Hosp       Date:  1990

Review 3.  Staphylococcal sepsis. The changing pattern of disease and therapy.

Authors:  S J Eykyn
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

4.  The use of nasal mupirocin ointment to prevent Staphylococcus aureus bacteraemias in haemodialysis patients: an analysis of cost-effectiveness.

Authors:  J R Boelaert; Y A De Baere; M A Geernaert; C A Godard; H W Van Landuyt
Journal:  J Hosp Infect       Date:  1991-09       Impact factor: 3.926

Review 5.  The antimicrobial activity of mupirocin--an update on resistance.

Authors:  B Slocombe; C Perry
Journal:  J Hosp Infect       Date:  1991-09       Impact factor: 3.926

Review 6.  Bacterial arthritis.

Authors:  D L Goldenberg; J I Reed
Journal:  N Engl J Med       Date:  1985-03-21       Impact factor: 91.245

7.  The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients.

Authors:  J R Boelaert; R A De Smedt; Y A De Baere; C A Godard; E G Matthys; M L Schurgers; R F Daneels; B Z Gordts; H W Van Landuyt
Journal:  Nephrol Dial Transplant       Date:  1989       Impact factor: 5.992

8.  Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis.

Authors:  V L Yu; A Goetz; M Wagener; P B Smith; J D Rihs; J Hanchett; J J Zuravleff
Journal:  N Engl J Med       Date:  1986-07-10       Impact factor: 91.245

9.  A prospective study of infections in hemodialysis patients: patient hygiene and other risk factors for infection.

Authors:  L G Kaplowitz; J A Comstock; D M Landwehr; H P Dalton; C G Mayhall
Journal:  Infect Control Hosp Epidemiol       Date:  1988-12       Impact factor: 3.254

10.  Impaired function of macrophage Fc gamma receptors in end-stage renal disease.

Authors:  P Ruiz; F Gomez; A D Schreiber
Journal:  N Engl J Med       Date:  1990-03-15       Impact factor: 91.245

View more
  2 in total

1.  American Society of Nephrology quiz and questionnaire 2012: renal replacement therapy.

Authors:  Rajnish Mehrotra; Richard J Glassock; Anthony J Bleyer
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-04       Impact factor: 8.237

2.  The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients.

Authors:  Yeohan Song; Julie H Y Tai; Sarah M Bartsch; Richard K Zimmerman; Robert R Muder; Bruce Y Lee
Journal:  Vaccine       Date:  2012-03-29       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.